The incidence of anti–tumour necrosis factor (TNF)–induced psoriasiform eruptions has ranged in the literature between 0.5% and 10.9% of patients with inflammatory bowel disease (IBD). The morphology of the rash varies, with plaque psoriasis being the most common form. Generalized pustular eruption is reported in 10.2% of cases of anti–TNF-induced psoriasis. We are reporting a unique case of anti–TNF-associated psoriasiform eruption due to the severity of the rash presenting as a generalized pustular eruption in association with plaque psoriasiform rash requiring systemic therapy.
BrownGWangELeonAet al. Tumor necrosis factor–alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334-341.
2.
LagaACVleugelsRAQureshiAAVelazquezEF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor–alpha inhibitor therapy: a study of 16 biopsies. Am J Dermatopathol. 2010;32:568-573.
3.
HellstromAEFarkkilaMKolhoKL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:563-571.
4.
FrelingEBaumannCCunyJFet al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186-1196.
5.
Peyrin-BirouletLPanésJSandbornWJet al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348-354.
6.
CollamerANBattafaranoDF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-240.
7.
NaldiLGambiniD. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510.
8.
MarzanoAVTavecchioSBertiEGelmettiCCugnoM. Paradoxical autoinflammatory skin reaction to tumor necrosis factor alpha blockers manifesting as amicrobial pustulosis of the folds in patients with inflammatory bowel diseases. Medicine. 2015;94:e1818.
9.
TillackCEhmannLMFriedrichMet al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577.
10.
DuffinKCKruegerGG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol. 2009;129:827-833.
11.
MaHNapierataLStedmanNet al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62:430-440.
12.
FunkJLangelandTSchrumpfEHanssenLE. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125(5):463-465.
13.
de GannesGCGhoreishiMPopeJet al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors inpatients with rheumatologic conditions. Arch Dermatol. 2007;143(2):223-231.
14.
CollamerANBattafaranoDF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-240.
15.
PijlsPAGilissenLP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects. Dig Liver Dis. 2016;48:1391-1393.
16.
PuglieseDGuidiLFerraroPMet al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880-888.
